

Prevalence of mixed pathologies in the aging brain

Alzheimer's Research and Therapy

6, 82

DOI: [10.1186/s13195-014-0082-1](https://doi.org/10.1186/s13195-014-0082-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Quantitative neuropathological assessment to investigate cerebral multi-morbidity. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 85.	3.0	27
2	Frailty and the risk of cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 54.	3.0	102
3	Patterns of Tau and β -Synuclein Pathology in the Visual System. <i>Journal of Parkinson's Disease</i> , 2015, 5, 333-340.	1.5	15
4	Progressive Supranuclear Palsy Syndrome and Semantic Dementia in Neuropathologically Proven Lewy Body Disease: A Report of Two Cases. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 95-101.	1.2	5
5	Cerebrospinal Fluid β 240 Improves the Interpretation of β 242 Concentration for Diagnosing Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 247.	1.1	49
6	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. <i>Frontiers in Neurology</i> , 2015, 6, 256.	1.1	16
7	Humic Acid Increases Amyloid β -Induced Cytotoxicity by Induction of ER Stress in Human SK-N-MC Neuronal Cells. <i>International Journal of Molecular Sciences</i> , 2015, 16, 10426-10442.	1.8	10
8	Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. <i>Acta Neuropathologica</i> , 2015, 129, 729-748.	3.9	168
9	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109
10	Effect of common neuropathologies on progression of late life cognitive impairment. <i>Neurobiology of Aging</i> , 2015, 36, 2225-2231.	1.5	24
11	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 757-762.	3.9	139
12	Challenges of multimorbidity of the aging brain: a critical update. <i>Journal of Neural Transmission</i> , 2015, 122, 505-521.	1.4	115
13	Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2016, 17, 189.	1.8	223
14	The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 373-392.	1.2	7
15	Sex on the brain: Unraveling the differences between women and men in neurodegenerative disease. <i>Nature Medicine</i> , 2016, 22, 1370-1372.	15.2	23
16	"New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 482-498.	0.9	130
17	Impact of Alzheimer's Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 42, 106-116.	0.7	16
18	Depletion of TDP-43 decreases fibril and plaque β -amyloid and exacerbates neurodegeneration in an Alzheimer's mouse model. <i>Acta Neuropathologica</i> , 2016, 132, 859-873.	3.9	43

#	ARTICLE	IF	CITATIONS
19	Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	3
20	Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 878-886.	1.8	127
21	CSF biomarkers in neurodegenerative and vascular dementias. <i>Progress in Neurobiology</i> , 2016, 138-140, 36-53.	2.8	34
22	Mapping CSF biomarker profiles onto NIA's guidelines for Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 587-597.	1.8	14
23	Astrocytes in neuroprotection and neurodegeneration: The role of connexin43 and pannexin1. <i>Neuroscience</i> , 2016, 323, 207-221.	1.1	54
24	Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. <i>Neurobiology of Aging</i> , 2017, 53, 83-92.	1.5	64
25	Subclinical white matter lesions and medial temporal lobe atrophy are associated with EEG slowing in a memory clinic cohort. <i>Clinical Neurophysiology</i> , 2017, 128, 1575-1582.	0.7	5
26	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017, 6, 8.	3.6	177
27	Evaluating the Patterns of Aging-Related Tau Astroglipathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 270-288.	0.9	98
28	Parkinson's Disease: Cognitive Impairment. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 42-54.	0.4	12
29	Genetic Alzheimer Disease and Sporadic Dementia With Lewy Bodies: A Comorbidity Presenting as Primary Progressive Aphasia. <i>Cognitive and Behavioral Neurology</i> , 2017, 30, 23-29.	0.5	13
30	Geroscience: Addressing the mismatch between its exciting research opportunities, its economic imperative and its current funding crisis. <i>Experimental Gerontology</i> , 2017, 94, 46-51.	1.2	12
31	Population Base Rates and Disease Course of Common Psychiatric and Neurodegenerative Disorders. <i>Neuropsychology Review</i> , 2017, 27, 284-301.	2.5	9
32	Mixed neuropathologies and associations with domain-specific cognitive decline. <i>Neurology</i> , 2017, 89, 1773-1781.	1.5	21
33	Vascular Pathology Causing Late Onset Generalized Chorea: A Clinico-Pathological Case Report. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 819-823.	0.8	2
34	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. <i>European Journal of Neurology</i> , 2017, 24, 1326.	1.7	71
35	Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action. <i>Neurochemistry International</i> , 2017, 108, 481-493.	1.9	34
36	Genetic resilience to amyloid related cognitive decline. <i>Brain Imaging and Behavior</i> , 2017, 11, 401-409.	1.1	32

#	ARTICLE	IF	CITATIONS
37	TDP β 43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. <i>Brain Pathology</i> , 2017, 27, 472-479.	2.1	170
38	Amygdala β -Synuclein Pathology in the Population-Based Vantaa 85+ Study. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 669-674.	1.2	6
39	Cognition and dementia in older patients with epilepsy. <i>Brain</i> , 2018, 141, 1592-1608.	3.7	177
40	Progression of Alzheimer's Disease-Related Pathology and Cell Counts in a Patient with Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1451-1462.	1.2	8
41	TDP-43 post-translational modifications in health and disease. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 279-293.	1.5	110
42	Conversion and time-to-conversion predictions of mild cognitive impairment using low-rank affinity pursuit denoising and matrix completion. <i>Medical Image Analysis</i> , 2018, 45, 68-82.	7.0	72
43	Ligand-cascading nano-delivery devices to enable multiscale targeting of anti-neurodegenerative therapeutics. <i>Biomedical Materials (Bristol)</i> , 2018, 13, 034102.	1.7	11
44	Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2018, 55, 7588-7605.	1.9	17
45	Concepts and classification of neurodegenerative diseases. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 145, 301-307.	1.0	109
46	Alpha-synucleinopathies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 145, 339-353.	1.0	50
47	Multiproteinopathy, neurodegeneration and old age: a case study. <i>Neurocase</i> , 2018, 24, 1-6.	0.2	2
48	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 2-20.	0.9	77
49	When Decrease β 1-42 in CSF May Not Mean Alzheimer's Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 359-363.	0.6	0
50	Age and the association of dementia-related pathology with trajectories of cognitive decline. <i>Neurobiology of Aging</i> , 2018, 61, 138-145.	1.5	32
51	Multiple neuronal pathologies are common in young patients with pathologically proven Frontotemporal lobar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 522-532.	1.8	9
52	Astroglipathy in Tauopathies. <i>Neuroglia (Basel, Switzerland)</i> , 2018, 1, 126-150.	0.3	24
53	Genetic variation within endolysosomal system is associated with late-onset Alzheimer's disease. <i>Brain</i> , 2018, 141, 2711-2720.	3.7	64
54	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018, 14, 639-652.	4.9	434

#	ARTICLE	IF	CITATIONS
55	Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 115-126.	1.2	133
56	Clinical dementia severity associated with ventricular size is differentially moderated by cognitive reserve in men and women. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 89.	3.0	11
57	Combined neuropathological pathways account for age-related risk of dementia. <i>Annals of Neurology</i> , 2018, 84, 10-22.	2.8	141
58	Comorbidities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 573-577.	1.0	4
59	The Revised National Alzheimer's Coordinating Center's Neuropathology Form Available Data and New Analyses. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 717-726.	0.9	116
60	Minimal neuropathologic diagnosis for brain banking in the normal middle-aged and aged brain and in neurodegenerative disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 150, 131-141.	1.0	8
61	Very old onset parkinsonism: A clinical-pathological study. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 39-43.	1.1	8
62	The Therapeutic Potential of Metformin in Neurodegenerative Diseases. <i>Frontiers in Endocrinology</i> , 2018, 9, 400.	1.5	203
63	Childhood Lead Exposure and Adult Neurodegenerative Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 17-42.	1.2	70
64	Prion protein stabilizes amyloid- β^2 (A β^2) oligomers and enhances A β^2 neurotoxicity in a <i>Drosophila</i> model of Alzheimer's disease. <i>Journal of Biological Chemistry</i> , 2018, 293, 13090-13099.	1.6	29
65	Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview. <i>Clinical Biochemistry</i> , 2019, 73, 26-31.	0.8	84
66	Molecular pathology of neurodegenerative diseases: principles and practice. <i>Journal of Clinical Pathology</i> , 2019, 72, 725-735.	1.0	130
67	Aging of bovine spinal cord: an alteration of myelinated nerve fibers in the white matter. <i>Comparative Clinical Pathology</i> , 2019, 28, 1137-1142.	0.3	0
68	Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial. <i>Neurobiology of Disease</i> , 2019, 130, 104530.	2.1	11
69	Extracellular vesicles as an emerging tool for the early detection of Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2019, 184, 111175.	2.2	47
70	Optimizing Machine Learning Methods to Improve Predictive Models of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1027-1036.	1.2	26
71	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019, 8, 28.	3.6	70
72	Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85+. <i>Acta Neuropathologica</i> , 2019, 138, 771-782.	3.9	46

#	ARTICLE	IF	CITATIONS
73	Type 2 Diabetes Mellitus Increases The Risk of Late-Onset Alzheimer's Disease: Ultrastructural Remodeling of the Neurovascular Unit and Diabetic Gliopathy. <i>Brain Sciences</i> , 2019, 9, 262.	1.1	48
74	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	1.5	51
75	Cognitive aging is not created equally: differentiating unique cognitive phenotypes in "normal" adults. <i>Neurobiology of Aging</i> , 2019, 77, 13-19.	1.5	41
76	Precision Aging: Applying Precision Medicine to the Field of Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 128.	1.7	37
77	Disentangling Heterogeneity in Alzheimer's Disease: Two Empirically-Derived Subtypes. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 227-239.	1.2	10
78	Dementias. , 2019, , 287-345.		2
79	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	3.7	873
80	Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases?. <i>Current Opinion in Neurology</i> , 2019, 32, 279-291.	1.8	30
81	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 263-276.	1.2	13
83	Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. <i>Laboratory Investigation</i> , 2019, 99, 993-1007.	1.7	60
84	Neuropathology-driven Whole-genome Sequencing Study Points to Novel Candidate Genes for Healthy Brain Aging. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 7-14.	0.6	1
85	<i>APOE</i> ϵ 4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia. <i>Neurology</i> , 2019, 93, e1807-e1819.	1.5	43
86	Association of Longitudinal β -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	2.8	22
87	Synaptic distributions of pS214 τ in rhesus monkey prefrontal cortex are associated with spine density, but not with cognitive decline. <i>Journal of Comparative Neurology</i> , 2019, 527, 856-873.	0.9	4
88	A third of community-dwelling elderly with intermediate and high level of Alzheimer's neuropathologic changes are not demented: A meta-analysis. <i>Ageing Research Reviews</i> , 2020, 58, 101002.	5.0	15
89	Cognitive reserve predicts future executive function decline in older adults with Alzheimer's disease pathology but not age-associated pathology. <i>Neurobiology of Aging</i> , 2020, 88, 119-127.	1.5	19
90	To stage, or not to stage. <i>Current Opinion in Neurobiology</i> , 2020, 61, 10-22.	2.0	37
91	Comorbid amyloid β pathology affects clinical and imaging features in VCD. <i>Alzheimer's and Dementia</i> , 2020, 16, 354-364.	0.4	6

#	ARTICLE	IF	CITATIONS
92	Brain frailty and small vessel disease for stroke outcome prediction. <i>Neurology</i> , 2020, 94, 191-192.	1.5	4
93	FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 133.	3.0	23
94	Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 575953.	1.1	45
95	Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12106.	1.2	4
96	Differential cross-seeding properties of tau and \hat{I} -synuclein in mouse models of tauopathy and synucleinopathy. <i>Brain Communications</i> , 2020, 2, fcaa090.	1.5	24
97	TRP Channels Role in Pain Associated With Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2020, 14, 782.	1.4	46
98	Neuropathological assessment of the Alzheimer spectrum. <i>Journal of Neural Transmission</i> , 2020, 127, 1229-1256.	1.4	34
99	Does Gender Influence the Relationship Between High Blood Pressure and Dementia? Highlighting Areas for Further Investigation. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 23-48.	1.2	17
100	Genetic variants and functional pathways associated with resilience to Alzheimer's disease. <i>Brain</i> , 2020, 143, 2561-2575.	3.7	93
101	Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 465-473.	0.9	17
102	Epidemiology of neurological diseases in older adults. <i>Revue Neurologique</i> , 2020, 176, 642-648.	0.6	45
103	Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. <i>JAMA Neurology</i> , 2020, 77, 1299.	4.5	109
104	Biomechanical response of the CNS is associated with frailty in NPH-suspected patients. <i>Journal of Neurology</i> , 2020, 267, 1389-1400.	1.8	8
105	Total daily physical activity, brain pathologies, and parkinsonism in older adults. <i>PLoS ONE</i> , 2020, 15, e0232404.	1.1	8
106	Astroglia and Tau: New Perspectives. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 96.	1.7	73
107	Oligomerization and Conformational Change Turn Monomeric \hat{I} -Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis. <i>Molecules</i> , 2020, 25, 1659.	1.7	60
108	Roles of glutamate receptors in a novel in vitro model of early, comorbid cerebrovascular, and Alzheimer's diseases. <i>Journal of Neurochemistry</i> , 2021, 156, 539-552.	2.1	4
109	Biophysical processes underlying cross-seeding in amyloid aggregation and implications in amyloid pathology. <i>Biophysical Chemistry</i> , 2021, 269, 106507.	1.5	101

#	ARTICLE	IF	CITATIONS
110	Multiple system agingâ€related tau astrogliopathy with complex proteinopathy in an oligosymptomatic octogenarian. <i>Neuropathology</i> , 2021, 41, 72-83.	0.7	11
111	Alzheimerâ€™s Disease Neuropathological Comorbidities are Common in the Younger-Old. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 389-400.	1.2	44
112	Coâ€incidental <i>C9orf72</i> expansion mutationâ€related frontotemporal lobar degeneration pathology and sporadic CreutzfeldtâˆJakob disease. <i>European Journal of Neurology</i> , 2021, 28, 1009-1015.	1.7	2
113	Relationship between Hearing Loss and Dementia Differs According to the Underlying Mechanism.		

#	ARTICLE	IF	CITATIONS
130	Diagnostic biomarkers in Alzheimer's disease. Biomarkers in Neuropsychiatry, 2021, 5, 100041.	0.7	12
133	Pathobiological Subtypes of Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2020, 49, 321-333.	0.7	33
134	Time course of dementia following sepsis in German health claims data. Neurology: Neuroimmunology and Neuroinflammation, 2021, 8, .	3.1	12
135	Neuropathological diagnoses and clinical correlates in older adults in Brazil: A cross-sectional study. PLoS Medicine, 2017, 14, e1002267.	3.9	90
136	Cross-seeding of prions by aggregated β -synuclein leads to transmissible spongiform encephalopathy. PLoS Pathogens, 2017, 13, e1006563.	2.1	42
137	Key Peptides and Proteins in Alzheimer's Disease. Current Protein and Peptide Science, 2019, 20, 577-599.	0.7	30
138	The CSF p-tau181/A β 242 Ratio Offers a Good Accuracy <i>in Vivo</i> in the Differential Diagnosis of Alzheimer's Dementia. Current Alzheimer Research, 2019, 16, 587-595.	0.7	17
139	A gut bacterial amyloid promotes β -synuclein aggregation and motor impairment in mice. ELife, 2020, 9, .	2.8	251
140	Reducing Your Risk of Alzheimer's Dementia: Building a Better Brain as We Age. Archives of Clinical Neuropsychology, 2021, 36, 1257-1265.	0.3	2
141	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. Journal of Clinical Medicine, 2021, 10, 4582.	1.0	9
142	Clinical Neuropathology teaching case 4-2015: Heterogenous brain pathologies temporally and spatially coinciding in limbic regions. , 2015, 34, 178-180.		0
143	Biomarkers of Alzheimer's Disease. Mental Health and Illness Worldwide, 2017, , 1-35.	0.1	0
144	Biomarkers of Alzheimer's Disease. Mental Health and Illness Worldwide, 2017, , 105-139.	0.1	0
147	Brain Ageing and Cognitive Impairment. Advances in Medical Diagnosis, Treatment, and Care, 2018, , 152-173.	0.1	0
148	Public Health Approaches to Alzheimer's Disease. , 2019, , 101-119.		0
149	Neurodegenerative Disorders. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 195-216.	0.1	0
150	Biological Signatures of Disease in Neuro-Psychiatry as Inter-Theoretical Reduction. Current Topics in Medicinal Chemistry, 2020, 20, 746-746.	1.0	0
153	Association between WWOX/MAF variants and dementia-related neuropathologic endophenotypes. Neurobiology of Aging, 2022, 111, 95-106.	1.5	6

#	ARTICLE	IF	CITATIONS
154	Psychopharmacologic treatment. , 2020, , 315-399.		1
155	Centenarians as Models of Resistance and Resilience to Alzheimerâ€™s Disease and Related Dementias. Advances in Geriatric Medicine and Research, 2020, 2, .	0.6	8
156	Mixed dementia. , 2020, , 3-15.		1
158	Assessment of neurovascular coupling and cortical spreading depression in mixed mouse models of atherosclerosis and Alzheimerâ€™s disease. ELife, 2022, 11, .	2.8	12
159	Synapses, Microglia, and Lipids in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 778822.	1.4	10
160	Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials. Neurotherapeutics, 2022, 19, 8-25.	2.1	26
161	Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimerâ€™s Disease. Cells, 2022, 11, 436.	1.8	18
162	Primary ageâ€related tauopathy in a Finnish populationâ€based study of the oldest old (Vantaa 85+). Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	6
163	Predictors of Life Expectancy in Autopsy-Confirmed Alzheimerâ€™s Disease1. Journal of Alzheimer's Disease, 2022, 86, 271-281.	1.2	4
164	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Frontiers in Neurology, 2021, 12, 750543.	1.1	6
165	Neuropathological lesions and their contribution to dementia and cognitive impairment in a heterogeneous clinical population. Alzheimer's and Dementia, 2022, 18, 2403-2412.	0.4	4
166	Recent update on the heterogeneity of the Alzheimerâ€™s disease spectrum. Journal of Neural Transmission, 2022, 129, 1-24.	1.4	37
167	OUP accepted manuscript. Brain, 2022, , .	3.7	0
168	Executive Functions in Alzheimerâ€™s Disease: A Systematic Review. Journal of Alzheimer's Disease Reports, 2022, 6, 81-99.	1.2	1
169	Current Concepts of Mixed Pathologies in Neurodegenerative Diseases. Canadian Journal of Neurological Sciences, 2023, 50, 329-345.	0.3	22
170	Translational approaches to understanding resilience to Alzheimerâ€™s disease. Trends in Neurosciences, 2022, 45, 369-383.	4.2	28
171	Exosomes in Age-Related Cognitive Decline: Mechanistic Insights and Improving Outcomes. Frontiers in Aging Neuroscience, 2022, 14, 834775.	1.7	4
172	Exploring common genetic contributors to neuroprotection from amyloid pathology. Brain Communications, 2022, 4, fcac066.	1.5	10

#	ARTICLE	IF	CITATIONS
173	Apolipoprotein E Proteinopathy Is a Major Dementia-Associated Pathologic Biomarker in Individuals with or without the APOE Epsilon 4 Allele. <i>American Journal of Pathology</i> , 2022, 192, 564-578.	1.9	6
176	Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease. <i>Neurology</i> , 2022, 98, .	1.5	10
177	Neuropathological associations of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) differ between the oldest-old and younger-old. <i>Acta Neuropathologica</i> , 2022, 144, 45-57.	3.9	10
178	Disentangling Alzheimer's disease neurodegeneration from typical brain ageing using machine learning. <i>Brain Communications</i> , 2022, 4, .	1.5	12
179	Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease. <i>Neurology</i> , 2022, 99, .	1.5	11
180	Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology. <i>Brain Pathology</i> , 2022, 32, .	2.1	6
181	Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. <i>Acta Neuropathologica</i> , 2022, 144, 27-44.	3.9	67
182	Pharmacotherapy for Alzheimer's disease: what's new on the horizon?. <i>Expert Opinion on Pharmacotherapy</i> , 0, , 1-19.	0.9	1
183	The unique effect of TDP-43 on hippocampal subfield morphometry and cognition. <i>NeuroImage: Clinical</i> , 2022, 35, 103125.	1.4	3
184	Identification and immunological characterization of cuproptosis-related molecular clusters in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	33
185	Identification of endoplasmic reticulum stress-associated genes and subtypes for prediction of Alzheimer's disease based on interpretable machine learning. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
186	Poststroke Cognitive Impairment: A Longitudinal Follow-Up and Pre/Poststroke Mini-Mental State Examination Comparison. <i>Current Alzheimer Research</i> , 2022, 19, 716-723.	0.7	4
187	Longitudinal change in serial position scores in older adults with entorhinal and hippocampal neuropathologies. <i>Journal of the International Neuropsychological Society</i> , 2023, 29, 561-571.	1.2	3
188	Association of Stroke and Cerebrovascular Pathologies With Scam Susceptibility in Older Adults. <i>JAMA Neurology</i> , 2023, 80, 49.	4.5	3
189	Mixed Pathologies in a Subject with a Novel PSEN1 G206R Mutation. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1601-1614.	1.2	1
190	The Burden of Dementia Spectrum Disorders and Associated Comorbid and Demographic Features. <i>Clinics in Geriatric Medicine</i> , 2022, , .	1.0	0
191	Morphometric imaging biomarker identifies Alzheimer's disease even among mixed dementia patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
192	Cognitive resistance to and resilience against multiple comorbid neurodegenerative pathologies and the impact of APOE status. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 110-119.	0.9	11

#	ARTICLE	IF	CITATIONS
193	Design and application of a customizable relational <scp>DataBase</scp> to assess clinicopathological correlations and concomitant pathology in neurodegenerative diseases. Brain Pathology, 2023, 33, .	2.1	3
194	Update on Alzheimerâ€™s Disease. European Medical Journal Neurology, 0, , 82-90.	0.0	1
195	The Vascular-Immune Hypothesis of Alzheimerâ€™s Disease. Biomedicines, 2023, 11, 408.	1.4	5
196	Association between anxiety symptoms and Alzheimer's disease biomarkers in cognitively healthy adults: A systematic review and meta-analysis. Journal of Psychosomatic Research, 2023, 166, 111159.	1.2	3
197	New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 5383.	1.8	7
198	Brain FDG PET for visualizing the relation between impaired lung function and cognitive decline in lung cancer: a preliminary study. Nuclear Medicine Communications, 0, Publish Ahead of Print, .	0.5	1
199	Cognitive heterogeneity reveals molecular signatures of age-related impairment. , 2023, 2, .		1
208	Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight. Nature Reviews Neuroscience, 2023, 24, 620-639.	4.9	9
224	Current trends and updates in the treatment of Alzheimer's disease. , 2024, , 373-390.		1